Mount Yale Investment Advisors LLC Buys 1,514 Shares of AbbVie Inc. (NYSE:ABBV)

Mount Yale Investment Advisors LLC grew its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,552 shares of the company's stock after acquiring an additional 1,514 shares during the quarter. Mount Yale Investment Advisors LLC's holdings in AbbVie were worth $5,074,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Atlanta Consulting Group Advisors LLC acquired a new stake in AbbVie in the third quarter valued at about $999,000. Saturna Capital Corp increased its position in AbbVie by 486.1% in the 3rd quarter. Saturna Capital Corp now owns 676,176 shares of the company's stock valued at $133,531,000 after acquiring an additional 560,808 shares during the period. Everence Capital Management Inc. raised its stake in shares of AbbVie by 41.3% during the fourth quarter. Everence Capital Management Inc. now owns 53,171 shares of the company's stock valued at $9,448,000 after acquiring an additional 15,550 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of AbbVie by 9.5% during the fourth quarter. GAMMA Investing LLC now owns 39,453 shares of the company's stock worth $7,011,000 after purchasing an additional 3,439 shares during the period. Finally, Avior Wealth Management LLC raised its position in AbbVie by 23.5% during the 3rd quarter. Avior Wealth Management LLC now owns 56,556 shares of the company's stock worth $11,169,000 after purchasing an additional 10,768 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on ABBV. Wells Fargo & Company raised their price target on shares of AbbVie to $195.00 and gave the stock a "buy" rating in a report on Tuesday, November 19th. Truist Financial decreased their price objective on AbbVie from $215.00 to $211.00 and set a "buy" rating for the company in a report on Wednesday, January 8th. Citigroup reduced their price target on shares of AbbVie from $215.00 to $205.00 and set a "buy" rating for the company in a research report on Tuesday. TD Cowen boosted their target price on shares of AbbVie from $195.00 to $225.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Finally, Piper Sandler raised their price target on shares of AbbVie from $212.00 to $220.00 and gave the company an "overweight" rating in a research report on Tuesday, December 17th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average price target of $205.00.

AbbVie Trading Down 1.1 %

NYSE:ABBV traded down $2.02 during mid-day trading on Tuesday, hitting $174.88. 5,603,615 shares of the stock traded hands, compared to its average volume of 6,088,012. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm's 50 day moving average is $176.05 and its two-hundred day moving average is $184.94. AbbVie Inc. has a 52 week low of $153.58 and a 52 week high of $207.32. The stock has a market capitalization of $309.04 billion, a price-to-earnings ratio of 60.72, a PEG ratio of 1.68 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $3.00 EPS for the quarter, beating analysts' consensus estimates of $2.92 by $0.08. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The company's revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.95 EPS. On average, equities research analysts predict that AbbVie Inc. will post 10.06 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be paid a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.75%. This is a positive change from AbbVie's previous quarterly dividend of $1.55. AbbVie's dividend payout ratio is presently 227.78%.

Insider Activity at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.25% of the company's stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.